News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.
Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.
The funding will be used to support clinical validation and expand market access for the firm's endometriosis diagnostic test.
